歸創通橋-B(02190.HK):Zynlastic外周靜脈支架系統完成臨牀試驗患者招募
格隆匯7月12日丨歸創通橋-B(02190.HK)宣佈,截至2021年7月12日,公司已完成Zynlastic外周靜脈支架系統(Zynlastic)的臨牀試驗患者招募程序。Zynlastic是公司外周血管產品組合的主要候選產品。公司的外周靜脈支架系統乃用於治療髂靜脈狹窄或髂靜脈受壓綜合徵(IVCS)等閉塞性疾病。
公司計劃於12個月隨訪後於2022年第四季度初向國家藥品監督管理局(國家藥監局)提交為Zynlastic註冊的申請,較先前於公司日期為2021年6月22日的招股章程所披露的時間表(即2023年第二季度)提前約六個月,並預期於2023年為Zynlastic取得國家藥監局的批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.